Navigation Links
New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
Date:9/18/2007

cure rate compared to a 79.8% cure rate seen with the combination of piperacillin/tazobactam. The study also highlighted that resistance to piperacillin/tazobactam in bacteria causing pneumonia was higher than doripenem, especially among strains of Pseudomonas aeruginosa and Klebsiella pneumoniae.

A second study demonstrated that 500 mg of doripenem administered intravenously every eight hours (500 mg IV q8h) was as clinically effective and well tolerated as standard therapy with imipenem given as 500 mg intravenously every six hours (500 mg IV q6h) or 1 g every eight hours (1 g IV q8h) in patients with ventilator-associated pneumonia, including in high-risk patients, such as the elderly. Overall clinical cure rates were 68.3% for doripenem and 64.8% for imipenem. For those patients with Pseudomonas aeruginosa infection, doripenem demonstrated a 65% clinical cure rate compared to a 36% clinical cure rate seen with imipenem.

"These studies demonstrate that doripenem may be effective against a major cause of nosocomial pneumonia, Pseudomonas aeruginosa, which is one of the most difficult bacteria to treat," said Michael Niederman, M.D., Professor of Medicine, State University of New York at Stony Brook and Chairman of the Department of Medicine at Winthrop University Hospital in Mineola, New York. "Additionally, these troubling bacteria demonstrated a low rate of resistance to doripenem, which is an important factor in determining which antibiotic may work most effectively against the infection."

The use of doripenem in the treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is under standard regulatory review in the United States and Europe. These data, along with the regulatory submissions, demonstrate the ongoing commitment of Johnson & Johnson Pharmaceutical Research & Development, L.L.C., to developing novel drugs for the anti-infective market.

Study Results

In a Phase III, open-label, randomized, multi-cent
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,
L.L.C.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
8. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
9. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
10. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
11. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/zkkg9q/blood_processing ) has announced ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... 2014 through 2020. Also, a seven-year historic analysis is provided ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/sn8mlw/picture_archiving ) ... Communication Systems (PACS) - Global Strategic Business Report" report ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ... are provided for the period 2014 through 2020. Also, a ...
(Date:6/2/2015)... , June 2, 2015 Today the ... over 150 major food companies, retailers, and human ... Forum on Antibiotic Stewardship. CSTE is committed to ... bacteria, detect resistant strains, preserve the efficacy of ... resistant infections. CSTE continues to serve ...
Breaking Medicine Technology:Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 2Blood Processing Supplies and Equipment Market - Global Strategic Business Report 2015-2020 3Picture Archiving and Communication Systems (PACS) - Global Strategic Business Report 2015: User Demand Favors Integrated RIS/PACS Solutions 2
... 2011 Results from a two-year retrospective cohort study ... Academy of Neurology (AAN), Hawaii, U.S., showed that patients ... including hypertension, cardiac dysrhythmias and chronic ischemic heart diseases ... controls without RLS. "These findings suggest ...
... Pharmaceuticals, Inc. (AMEX: AEN ), a developer ... announced today top-line results from its clinical study evaluating ... disease (AD) and mild cognitive impairment (MCI). The clinical ... and decreasing serum free copper. In addition, secondary outcomes ...
Cached Medicine Technology:New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 2New Research Links Restless Legs Syndrome (RLS) to Cardiovascular Disease 3Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 2Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 3Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 4Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 5Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 6Adeona's Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper 7
(Date:6/2/2015)... 02, 2015 On Wednesday, May 27, 2015, ... to a top speed of 207.9 mph. In the ... to break the 200 mph mark. Jay Leno was ... upcoming episode of Jay Leno’s Garage, which will air on ... the 8.5 mile high speed oval at the Continental Tire ...
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations ... expand urgent care services in Los Angeles County. ... of California Board of Regents and the Exer Board ... to purchase a minority share of four existing Exer ... and Northridge and creates opportunity to grow and develop ...
(Date:6/2/2015)... Prussia, PA (PRWEB) June 02, 2015 ... Outsourcing solutions for health plans in the Medicare Advantage, ... participation as a sponsor and exhibitor at AHIP’s Institute ... America’s Health Insurance Plans. The conference will be held ... exhibition booth, #1303, will offer opportunities for attendees to ...
(Date:6/2/2015)... June 02, 2015 On October 1, ... efforts for another delay. , On Monday, June ... Subcommittee for the House Ways and Means Committee, and ... Centers for Medicare and Medicaid Services, urging the administration ... CMS rolls out ICD-10. ICD-10 is the newest coding ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 IMPAK ... sorbent systems, has announced the availability of “child-resistant” ... of poisons by children, especially curious toddlers. The ... standards and tested to CFR 1700.20 protocols. The ... Cullen. , Looks Like Candy, “With the proliferation ...
Breaking Medicine News(10 mins):Health News:774 HP Hennessey Mustang Tested to 207.9 mph 2Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:TMG Health to Sponsor and Exhibit at AHIP’s Institute 2015 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 2Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 3Health News:HomeTown Health Launches a “100 Day Countdown” in Response to ICD-10 Survey 4Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2
... MINNEAPOLIS, Dec. 18 MinuteClinic medical clinics in select ... now offering H1N1 vaccinations on demand seven days a ... be obtained at MinuteClinic locations in Maryland in Baltimore ... in North Carolina in Charlotte, Greensboro, Winston-Salem and Raleigh-Durham; ...
... people who have received solid organ transplants and veterinarians should ... That,s just one of the key pieces of advice from ... in the American Journal of Transplantation . ... by members of the American Society of Transplantation,s Infectious Diseases ...
... understanding of TAK1 could lead to new treatments for ... News) -- A protein switch called TAK1 helps prevent ... a team of scientists from the United States and ... improve understanding about the development of liver disease and ...
... , ... Operations to offer enhanced capabilities , ... Milford, NH and Marlboro, MA (PRWEB) December 18, 2009 -- Degree ... electronics and telecommunications industries, announced today that it has sold its IQS Testing business ...
... ... connect with clients and prospective clients, , ... Glendale, CA (Lexis Nexis) December 18, 2009 -- Milton & DeKruif, a Glendale ... it has kicked off an aggressive new client development campaign in order to raise its ...
... ... and create applications on all of their software and hardware platforms -- both new ... ... Systems announced a detailed 2010 product roadmap for NXTware Remote, its Eclipse-based cross-platform ...
Cached Medicine News:Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 2Health News:CVS MinuteClinic Now Providing H1N1 Vaccinations On Demand at all Locations in Maryland, North Carolina and Tennessee 3Health News:Transplant guide highlights daily infection risks from factors like pets and food 2Health News:Transplant guide highlights daily infection risks from factors like pets and food 3Health News:IQS Testing Purchased by The Compliance Management Group 2Health News:IQS Testing Purchased by The Compliance Management Group 3Health News:Milton & DeKruif Launches New Client Development Campaign 2Health News:eCube Announces 2010 NXTware Remote Product Roadmap 2Health News:eCube Announces 2010 NXTware Remote Product Roadmap 3Health News:eCube Announces 2010 NXTware Remote Product Roadmap 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: